Mohammad Asad

Mohammad Asad

Auto-generated profile, based on publicly available information

Mohammad Asad

Department of Neurological Surgery, Albert Einstein College of Medicine/Montefiore Medical Center , Bronx

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
SDSonali Das
Sonali Das
ABAnindyajit Banerjee
Anindyajit Banerjee
MKMohd. Kamran
Mohd. Kamran
SESarfaraz Ahmad Ejazi
Sarfaraz Ahmad Ejazi
MAMohammad Asad
Mohammad Asad
SCSaikat Chakrabarti
Saikat Chakrabarti
Emergence of resistance to available anti-leishmanial drugs advocates identification of new drug targets and their inhibitors for visceral leishmaniasis. Here, we identified heat shock protein 78 in Leishmania donovani (LdHSP78), a putative ClpB protease, as important for parasite infection of host macrophages and a potential therapeutic target. Enrichment of LdHSP78 in infected humans, hamsters and parasite amastigotes suggested its importance for disease persistence. Heterozygous knockouts of L. donovani (LdHSP78+/-) and L. mexicana (LmxHSP78+/-) were generated using flanking untranslated region (UTR) based multi-fragment ligation strategy and CRISPR-Cas9 technique, respectively to investigate the significance of HSP78 for disease manifestation. LdHSP78+/- parasite burden was dramatically reduced in both murine bone marrow–derived macrophages and hamsters, associated with enrichment of pro-inflammatory cytokines and nitric oxide (NO). This finding implies that LdHSP78+/- parasites cannot suppress immune activation and escape NO-mediated toxicity in macrophages. Further, phosphorylation of the mitogen-activated protein kinase (MAPK) p38 was enhanced, and phosphorylation of extracellular signal–regulated kinase 1/2 (ERK1/2) was decreased in cells infected with LdHSP78+/- compared to wildtype (WT) infection. Virulence of the LdHSP78+/- strain was restored by episomal addition of LdHSP78 gene. Finally, using high-throughput virtual screening, we identified P1,P5-di(adenosine-5’)-penta-phosphate ammonium salt (Ap5A) as an LdHSP78 inhibitor. It selectively induced amastigote death at doses similar to amphotericin B (AmB) dosing, while exhibiting much less cytotoxicity toward healthy macrophages than AmB. In summary, using both a genetic knockout approach and pharmacological inhibition, we establish LdHSP78 as a drug target and Ap5A as a potential lead for improved anti-leishmanial agents.

12 August 2021 in The FASEB Journal
Verified
Journal Article
Closed access
PDF file
MAMohammad Asad
Mohammad Asad
ASAbdus Sabur
Abdus Sabur
MKMohd Kamran
Mohd Kamran
SHShadab
Shadab
SDSonali Das
Sonali Das
Nahid AliNahid Ali
Nahid Ali

26 December 2021 in Allergy
Verified
Journal Article
Closed access
PDF file
AAAnand Kumar Andiappan
Anand Kumar Andiappan
MAMohammad Asad
Mohammad Asad
CCCeline Chua
Celine Chua
ESEsha Sehanobish
Esha Sehanobish
ZRZhen Ren
Zhen Ren
EJElina Jerschow
Elina Jerschow

3 November 2021 in Current Opinion in Allergy and Clinical Immunology
Verified
Journal Article
Open access
ESEsha Sehanobish
Esha Sehanobish
MAMohammad Asad
Mohammad Asad
EJElina Jerschow
Elina Jerschow
Purpose of review: The purpose of this review is to provide a comprehensive summary of the current understanding of the pathogenesis of aspirin-exacerbated respiratory disease (AERD), and an update on its management. Recent findings: Elevated levels of 15-oxo-eicosatetraenoic acid (15-Oxo-ETE), a newly described metabolite of arachidonic acid, have been identified in nasal polyps of AERD patients. In nasal polyps, activated basophils, and interleukin-5 -receptor-α-positive IL-5Rα+ plasma cells are associated with more severe nasal polyposis in AERD. Alveolar monocyte-derived macrophages and their persistent proinflammatory activation were suggested as putative factors contributing to AERD. Although not AERD-specific, three biological agents are now available for the management of both nasal polyposis and asthma. Summary: A newly downstream product of 15-lipoxygenase, 15-Oxo-ETE, was recently found to be significantly elevated in nasal polyps from AERD patients. This eicosanoid metabolite likely originates from an interplay between epithelial cells and mast cells. Nasal polyp basophils, IL-5Rα+ plasma cells, and alveolar macrophages were identified as important contributors to inflammation in AERD. Besides traditional aspirin desensitization and treatment for AERD management, several biologics for treatment of asthma are available, including three that have been approved for nasal polyposis. These biologic agents show variable rates of success in controlling AERD symptoms.

25 February 2026 in Neuro-Oncology
Verified
Journal Article
Closed access
MAMohammad Asad
Mohammad Asad
JIJulio Inocencio
Julio Inocencio
SMStefan Mitrasinovic
Stefan Mitrasinovic
MAMinori Aoki
Minori Aoki
CBCarly E Baker
Carly E Baker
BHBenjamin T Himes
Benjamin T Himes
Background: Immunotherapy has yet to make significant gains in glioblastoma (GBM) treatment, due in part to GBM-mediated immune suppression. Increasing evidence points to critical roles for tumor-derived extracellular vesicles (EVs) and immunosuppressive myeloid cells as key factors in this process. Methods: Immunophenotyping of the tumor-immune microenvironment was performed using ultrasonic aspirate collected during GBM resection by high-dimensional flow cytometry. EVs collected from patient-derived GBM cell lines were used to condition myeloid cells collected from healthy donors to generate immunosuppressive myeloid cells. siRNA was used to knockdown TIGIT and/or NLRP3 expression prior to EV conditioning. T cell co-culture studies were performed with donor-matched T cells. Results: Immune phenotyping of the tumor microenvironment and EV-conditioned myeloid cells revealed similar immunomodulatory protein expression across myeloid cell populations, with particularly elevated TIGIT expression. Knockdown of TIGIT reduced the immunosuppressive polarization of myeloid cells, resulting in improved T cell function. This finding proceeded in an NLRP3-dependent manner, with substantial co-expression of TIGIT and NLRP3 expression prior to knockdown, and concomitant knockdown of NLRP3 abrogating the effect of TIGIT knockdown. TIGIT expression correlated with increased IL-13 expression, and IL-13 blockade unmasked a pro-inflammatory myeloid cell phenotype. Conclusion: TIGIT expression in myeloid cells in the GBM microenvironment is a functional marker of immunosuppressive activity, with TIGIT knockdown reducing IL-13 expression and unmasking the pro-inflammatory activity of NLRP3. This study bolsters our understanding of the immunosuppressive complexities of the GBM microenvironment and supports attenuation of immunosuppressive myeloid cell activity as a strategy to restore immune function in GBM.

25 April 2025 in bioRxiv
Verified
Preprint
Open access
MAMohammad Asad
Mohammad Asad
JIJulio Inocencio
Julio Inocencio
SMStefan Mitrasinovic
Stefan Mitrasinovic
MAMinori Aoki
Minori Aoki
CCCelina Crisman
Celina Crisman
BHBenjamin T. Himes
Benjamin T. Himes
Glioblastoma (GBM) is a deadly brain cancer with near-universal recurrence despite maximal treatment for which new innovations are sorely needed. Immunotherapy has yet to make significant gains in GBM treatment despite revolutionizing other cancer therapies, due in part to GBM-mediated immune suppression. This immune derangement proceeds through several mechanisms, but increasing evidence points to critical roles for tumor-derived extracellular vesicles (EVs) and immunosuppressive myeloid cells as key factors in this process. In the present study, we demonstrate broad expression of TIGIT across myeloid cell populations in the GBM microenvironment, a finding recapitulated by conditioning healthy monocytes with GBM-derived EVs. Further, knockdown of TIGIT expression reduced the immunosuppressive polarization of monocytes, resulting in improvement in T cell function. This finding proceeded in an NLRP3-dependent manner, with substantial co-localization of TIGIT and NLRP3 expression prior to knockdown. These findings point to a novel role for TIGIT expression in diverse myeloid cells in the GBM microenvironment as a marker of immunosuppressive activity and further indicate a hierarchy of immunomodulatory protein activity in these myeloid cells, with TIGIT knockdown unmasking the pro-inflammatory activity of NLRP3. This study bolsters understanding of the immunosuppressive complexities of myeloid cells in the GBM microenvironment, while lending further support to prevention or attenuation of immunosuppressive myeloid cell activity as a means of restoring immune function in GBM. Graphical (Created in BioRender. Asad, M. (2025) https://BioRender.com/euiljoq Key Points: Tumor-mediated immune suppression is a key barrier to the development of effective immunotherapies for GBM. TIGIT is broadly expressed in myeloid cells within the GBM microenvironment and can be induced by GBM-derived extracellular vesicles. Knockdown of TIGIT reduces immunosuppressive polarization of monocytes and enhances T cell activity via NLRP3 signaling, implicating TIGIT expression as a targetable modifier of immunosuppressive activity in GBM-associated myeloid cells. Importance of the Study: Glioblastoma (GBM) remains a formidable clinical challenge, with poor prognosis and limited response to current immunotherapies. This study uncovers a novel immunosuppressive axis involving TIGIT expression in myeloid cells, which are key players in the GBM tumor microenvironment. By demonstrating GBM-derived extracellular vesicles induce TIGIT in healthy monocytes and TIGIT knockdown diminishes immunosuppressive polarization in an NLRP3-dependent manner, this study highlights TIGIT as both a marker and modulator of immune dysfunction in GBM. These findings introduce a functional hierarchy of immunoregulatory proteins in tumor-associated myeloid cells, positioning TIGIT as a potential checkpoint target. Restoring immune activity by disrupting this axis could enhance the efficacy of immunotherapy in GBM. Thus, this research not only advances our understanding of tumor-induced immune suppression but also opens a promising therapeutic avenue to reinvigorate anti-tumor immunity in a cancer type historically resistant to immunotherapeutic approaches.